Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Warren C. Fiskus, Prithviraj Bose, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Kevin Philip, Noor Alhamadani, Alicia Matthews, Sanam Loghavi, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2023-185089

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Taghi Manshouri, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 741.

https://doi.org/10.1182/blood-2023-185031

Published: 2023

Journal Articles

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis

Prithviraj Bose, Taghi Manshouri, Sharon D. Bledsoe, Nitin Jain, Lucia Masarova, Naveen Pemmaraju, Nakiuda Hall, Mary Ann Richie, Xuemei Wang, Hagop Kantarjian, Zeev E. Estrov, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2021-145750

Published: 2021

Journal Articles

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-140212

Published: 2020

Journal Articles

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood (2020) 135 (15): 1255–1269.

https://doi.org/10.1182/blood.2019002922

Published: 2020

Includes: Supplemental data

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD PhD, William G. Wierda, MD PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 3018.

https://doi.org/10.1182/blood-2019-124014

Published: 2019

Journal Articles

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

Taghi Manshouri, PhD, Ivo Veletic, MD, Ying Zhang, MD MS, Joseph E. Bove, IV, BS, Ping Li, PhD, David M. Harris, PhD, Zhiming Liu, BS, Evan N. Cohen, PhD, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 2961.

https://doi.org/10.1182/blood-2019-132054

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Blood (2019) 134 (Supplement_1): 3024.

https://doi.org/10.1182/blood-2019-124183

Published: 2019

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletic, Taghi Manshouri, Asha S. Multani, C. Cameron Yin, Lei Chen, Srdan Verstovsek, Zeev Estrov

Blood (2019) 133 (21): 2320–2324.

https://doi.org/10.1182/blood-2018-10-878926

Published: 2019

Includes: Supplemental data

Journal Articles

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, PhD, David N Saenz, Raffaella Soldi, Baohua Sun, MD PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Steven M. Kornblau, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lucia Masarova, MD, Steve Horrigan, Joseph David Khoury, MD, Sunil Sharma, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 177.

https://doi.org/10.1182/blood-2018-177

Published: 2018

Journal Articles

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

Taghi Manshouri, PhD, Ivo Veletic, MD, C. Cameron Yin, MD PhD, Lei Chen, MD, Joseph E. Bove, IV, Ying Zhang, MDMS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2018-99-119064

Published: 2018

Journal Articles

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srdan Verstovsek, MD PhD, Robert P. Hasserjian, MD, Olga Pozdnyakova, MD PhD, Ivo Veletic, MD, Ruben A. Mesa, MD, Lynda Foltz, MD FRCPC, John Mascarenhas, MD, Ellen K. Ritchie, MD, Jeanne Palmer, MD, Richard T. Silver, MD, Marina Kremyanskaya, MD PhD, Bernt van den Blink, MD PhD, Renu Gupta, MD, Taghi Manshouri, PhD, C. Cameron Yin, MD PhD, Zeev E. Estrov, MD, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 686.

https://doi.org/10.1182/blood-2018-99-115362

Published: 2018

Journal Articles

PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition

Ivo Veletic, MD, Taghi Manshouri, PhD, Graciela M. Nogueras González, MPH, Sanja Prijic, PhD, Joseph E. Bove, IV, Ying Zhang, MD MS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 5487.

https://doi.org/10.1182/blood-2018-99-119428

Published: 2018

Journal Articles

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, Yimin Qian, PhD, Kanak Raina, PhD, David N Saenz, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1239.

https://doi.org/10.1182/blood.V130.Suppl_1.1239.1239

Published: 2017

Journal Articles

SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations

Blood (2017) 130 (Supplement 1): 203.

https://doi.org/10.1182/blood.V130.Suppl_1.203.203

Published: 2017

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Myelofibrosis osteoclasts are clonal and functionally impaired

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only